首页> 美国卫生研究院文献>Biochemical Journal >125I-Labelled mapacalcine: a specific tool for a pharmacological approach to a receptor associated with a new calcium channel on mouse intestinal membranes.
【2h】

125I-Labelled mapacalcine: a specific tool for a pharmacological approach to a receptor associated with a new calcium channel on mouse intestinal membranes.

机译:125I-Labelled Mapacalcine:一种药理方法用于治疗与小鼠肠膜上新的钙通道相关的受体的特定工具。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mapacalcine is a small protein (Mr=19041) composed of two homologous chains purified from the marine sponge Cliona vastifica. Recently, we demonstrated that it was able to specifically block a Ca2+ channel which could not be related to already described channels on mouse intestinal myocytes. This Ca2+ current was insensitive to the known peptidic and organic calcium channel blockers. Mapacalcine was ineffective on T-type and L-type Ca2+ currents present on rat portal vein myocytes [Morel, Drobecq, Sautière, Tartar, Mironneau, Qar, Lavie, and Hugues (1997) Mol. Pharmacol. 51, 1042-1052]. We report here the preparation and purification of a monoiodo-derivative of mapa-calcine which retains its biological properties. Binding parameters of mapacalcine to its receptors have been characterized on mouse intestinal membranes. It binds to its receptors with a Kd=0. 8 nM, and a maximal binding capacity of 171 fmol/mg of protein on membrane preparations. Our data show that we have prepared a tool that is usable for pharmacological studies of a receptor associated with a new type of calcium channel for which no ligand was available until now.
机译:Mapacalcine是一种小蛋白质(Mr = 19041),由从海绵海巨球藻(Cliona hugeifica)纯化得到的两条同源链组成。最近,我们证明了它能够特异性阻断Ca2 +通道,而该通道可能与小鼠小肠肌细胞上已经描述的通道无关。此Ca2 +电流对已知的肽和有机钙通道阻滞剂不敏感。 Mapacalcine对大鼠门静脉肌细胞上存在的T型和L型Ca2 +电流无效[Morel,Drobecq,Sautière,Tartar,Mironneau,Qar,Lavie和Hugues(1997)Mol。 Pharmacol。 51,1042-1052]。我们在这里报告制备和纯化的mapa-calcine单碘衍生物保留其生物学特性。在小鼠肠膜上已经表征了马帕他汀与其受体的结合参数。它以Kd = 0与其受体结合。 8 nM,在膜制剂上的最大结合能力为171 fmol / mg蛋白质。我们的数据表明,我们已经准备了一种可用于与新型钙通道相关的受体进行药理学研究的工具,迄今为止尚没有针对其的配体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号